Literature DB >> 6294182

Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

K Handa, R Suzuki, H Matsui, Y Shimizu, K Kumagai.   

Abstract

In the accompanying paper, we showed that natural killer (NK) cells were a major population in the naive spleens of normal mice that responded directly to a T cell growth factor, interleukin 2 (IL 2), and clonally replicated without other stimulating agents. The cloned cells growing in IL 2 showed a potent NK activity against several NK targets without addition of an NK-activating agent, interferon (IFN). In the present study, therefore, we examined whether these cloned NK cells on their own produced IFN. It was found that all NK clones growing in IL 2 produced IFN in the culture fluids. The titers of IFN produced in the IL 2-containing media correlated well with the number of growing cells. With the culture in the absence of IL 2, neither cell growth nor IFN production could be detected. Addition of Con A into the culture in the IL 2-free media showed no IFN production. The antiserum neutralizing IFN alpha and IFN beta failed to significantly neutralize IFN produced by NK clones. Treatment with either a pH of 2.0 or antiserum neutralizing mouse IFN gamma resulted in a marked reduction of IL 2-induced NK IFN, indicating that a major part of IFN produced was IFN gamma. These results indicate that IL 2 stimulates NK clones to proliferate, accompanied by IFN gamma production. The results also show that an NK clone, when stimulated with Sendai virus, produced a type 1 IFN (IFN alpha and/or IFN beta), suggesting that murine NK cells can produce both type 1 (alpha and/or beta) and type 2 (gamma) IFN, depending on inducers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6294182

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.

Authors:  F Farace; C Mathiot; M Brandely; T Tursz; T Dorval; P Pouillart; F Triebel; T Hercend; W H Fridman
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer.

Authors:  H Mori; T Hanabayashi; Y Yamada; T Tamaya
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

3.  In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies.

Authors:  D A Leiby; A H Fortier; R M Crawford; R D Schreiber; C A Nacy
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

4.  Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.

Authors:  J W Mier; G Vachino; J W van der Meer; R P Numerof; S Adams; J G Cannon; H A Bernheim; M B Atkins; D R Parkinson; C A Dinarello
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

5.  Interferon-gamma (IFN-gamma) and interleukin-2 in the generation of lymphokine-activated killer cell cytotoxicity--IFN-gamma-induced suppressive activity.

Authors:  M Toledano; C Mathiot; J Michon; G Andreu; D Lando; M Brandely; W H Fridman
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  IgE receptor-positive non-B/non-T cells dominate the production of interleukin 4 and interleukin 6 in immunized mice.

Authors:  I Aoki; C Kinzer; A Shirai; W E Paul; D M Klinman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-gamma production of lymphocytes.

Authors:  S Ikemoto; S Wada; M Kamizuru; N Hayahara; T Kishimoto; M Maekawa
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Increased Ia expression, T lymphocyte subset abnormalities and autoimmunity in murine strains bearing the lpr gene.

Authors:  M J Dauphinée; N Talal
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

9.  Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages.

Authors:  P L Black; H Phillips; H R Tribble; R Pennington; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

10.  Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.

Authors:  Yihu Zheng; Kang Yu; Jimei Du; Lei Jiang; Shenghui Zhang; Yixiang Han; Panpan Yu; Yingxia Tan
Journal:  J Exp Clin Cancer Res       Date:  2010-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.